Bronchiolitis obliterans syndrome associated with an immune checkpoint inhibitor in a patient with non-small cell lung cancer
A 75-year-old woman was admitted to our hospital with progressive dyspnea 7 months after second-line treatment with pembrolizumab for advanced non-small cell lung cancer. Chest radiography revealed hyperinflation in both lung fields, and pulmonary function tests revealed severe obstructive dysfuncti...
Main Authors: | Kenichiro Takeda, Hideki Miwa, Masato Kono, Ryutaro Hirama, Yuiko Oshima, Yasutaka Mochizuka, Akari Tsutsumi, Yoshihiro Miki, Dai Hashimoto, Hidenori Nakamura |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-01-01
|
Series: | Respiratory Medicine Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007123000199 |
Similar Items
-
Immune dysregulation as a driver of bronchiolitis obliterans
by: Kuimiao Deng, et al.
Published: (2024-12-01) -
Postinfectious Bronchiolitis Obliterans
by: Aslı İmran Yılmaz, et al.
Published: (2021-12-01) -
Bronchiolitis Obliterans after Combination Immunotherapy with Pembrolizumab and Ipilimumab
by: Amulya Balagani, et al.
Published: (2018-07-01) -
Clinical Analysis and Risk Factors of Bronchiolitis Obliterans After Mycoplasma Pneumoniae Pneumonia
by: Zheng HQ, et al.
Published: (2022-07-01) -
Risk Factors for Post-infectious Bronchiolitis Obliterans in Children: A Systematic Review and Meta-Analysis
by: Die Liu, et al.
Published: (2022-06-01)